UroGen Pharma Ltd.
URGN
$9.87
-$0.27-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.98% | 9.29% | 15.64% | 17.22% | 24.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.98% | 9.29% | 15.64% | 17.22% | 24.00% |
| Cost of Revenue | 7.47% | -5.13% | -6.88% | -4.24% | 5.12% |
| Gross Profit | 9.15% | 11.13% | 18.74% | 20.26% | 26.66% |
| SG&A Expenses | 32.91% | 28.71% | 22.68% | 18.24% | 11.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.44% | 25.52% | 16.58% | 11.05% | 4.36% |
| Operating Income | -54.35% | -46.00% | -17.59% | -5.13% | 12.51% |
| Income Before Tax | -34.77% | -26.16% | -6.71% | -1.93% | 8.89% |
| Income Tax Expenses | -19.81% | -27.76% | 434.70% | 167.28% | 172.43% |
| Earnings from Continuing Operations | -32.70% | -24.09% | -9.78% | -4.16% | 6.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.70% | -24.09% | -9.78% | -4.16% | 6.53% |
| EBIT | -54.35% | -46.00% | -17.59% | -5.13% | 12.51% |
| EBITDA | -55.54% | -47.30% | -18.36% | -5.64% | 12.38% |
| EPS Basic | 3.59% | 16.07% | 28.37% | 32.58% | 32.12% |
| Normalized Basic EPS | 3.12% | 15.86% | 30.45% | 33.99% | 33.52% |
| EPS Diluted | 3.59% | 16.07% | 28.37% | 32.58% | 32.12% |
| Normalized Diluted EPS | 3.12% | 15.86% | 30.45% | 33.99% | 33.52% |
| Average Basic Shares Outstanding | 35.20% | 42.38% | 49.94% | 53.66% | 40.39% |
| Average Diluted Shares Outstanding | 35.20% | 42.38% | 49.94% | 53.66% | 40.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |